The primary aims of this study were to evaluate the proportion of MUC5B promoter polymorphism in different subtypes of ILD and to establish diagnostic cut-offs for serum KL-6 and MMP7 to distinguish ILD patients from healthy controls. Here, MUC5B is linked to interstitial lung disease.